Johnson & Johnson COVID-19 vaccine produces strong results

▴ Johnson & Johnson COVID-19 vaccine produces strong results
The vaccine, called Ad26.COV2.S, was equally well-tolerated at two different doses, the results showed

A single dose of Johnson & Johnson's experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, according to interim results published on Friday.

The vaccine, called Ad26.COV2.S was equally well-tolerated at two different doses, the results showed. A single shot, versus a rival two-dose approach being tested by Moderna Inc and Pfizer Inc, could simplify the distribution of the vaccine.

However, it is unclear whether elderly people, one of the populations most at risk from the virus, will be protected to the same degree as younger people with the J&J vaccine.

The trial in close to 1,000 healthy adults, which is backed by the U.S. government, began after the J&J vaccine was found in July to offer strong protection in a single dose to monkeys.

Based on the current results, J&J on Wednesday kicked off a final 60,000-person trial, which could pave the way for an application for regulatory approval. The company said it expects results of that so-called Phase 3 trial by the end of the year or early next year.

The results, released on the medical website medRxiv, have not been peer-reviewed. (https://bit.ly/2G3Ni1X)

Researchers, including those from J&J's unit Janssen Pharmaceuticals, said 98% of participants with data available for the interim analysis had neutralizing antibodies, which defend cells from pathogens, 29 days after vaccination.

However, immune response results were available from only a small number of people - 15 participants - over 65 years old, limiting the interpretation.

In participants older than 65, the rate of adverse reactions such as fatigue and muscle aches was 36%, much lower than the 64% seen in younger participants, the results showed, suggesting the immune response in older people may not be as strong.

The researchers said more details on safety and effectiveness will follow when the study is completed.

For now, the results justify why more studies are needed in larger numbers to look for serious adverse effects, Dr. Barry Bloom, a professor at Harvard T.H. Chan School of Public Health who was not involved in the J&J trial, told Reuters.

"Overall, the vaccine is doing what you would expect it to do if you were to move it to Phase 3 trials," Bloom said.

Tags : #JohnsonJohnson #COVID-19 #Result #Immunity

About the Author


Dr. Naila Syed

A well presented, self-motivated, and confident writer. Passionate about educating the masses on medical and nonmedical ways to promote health and lifestyle through my mighty pen.You can write to me at [email protected]

Related Stories

Loading Please wait...
-Advertisements-

Trending Now

China ropes in more countries for its COVID-19 vaccine trialsSeptember 29, 2020
Antarctica is still free of Covid-19. Can it stay that way?September 29, 2020
Over 200 travellers from India barred from Dubai flight over invalid Covid-19 testsSeptember 29, 2020
Netherland focuses on more stricker rule to comabt COVID-19 September 29, 2020
WHO aims to provide 120 Million rapid Coronavirus tests for poorer statesSeptember 29, 2020
UN chief on 1 Million COVID-19 deathsSeptember 29, 2020
Bahrain reports 585 Covid-19 cases, 777 recoveriesSeptember 28, 2020
Bringing hepatitis C testing and treatment to underserved communities in MadridSeptember 28, 2020
Polish doctor recovers from severe COVID-19 through rehabilitationSeptember 28, 2020
WHO supports rehabilitation of COVID-19 and other patients in UkraineSeptember 28, 2020
WHO work with migrant camps in Greece September 28, 2020
US employers being sued for COVID-19 infection spread September 28, 2020
Global Coronavirus deaths cross 1 Million markSeptember 28, 2020
Highly effective antibodies identified, may lead to passive COVID-19 vaccineSeptember 26, 2020
Europe has a lot of work to do to prevent COVID-19 transmission :WHOSeptember 26, 2020
Two million Coronavirus deaths : WHO September 26, 2020
Johnson & Johnson COVID-19 vaccine produces strong results September 26, 2020
New York to permanently switch to outdoor dining amid pandemicSeptember 26, 2020
WHO gave blessing for Coronavirus vaccine emergency use programme: ChinaSeptember 26, 2020
US surpasses 7 Million Coronavirus casesSeptember 26, 2020